IV tPA for acute ischemic stroke: Results of the first 101 patients in a community practice

Neurologist

Volumn 11, Issue 5, 2005, Pages 305-308

  Dick, Arthur P ^a   Straka, Janet ^a  

^a Arthur P Dick Neurology Inc   (United States)

Author keywords

Intracranial hemorrhage; Ischemic stroke; Thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMMUNITY CARE; COMMUNITY HOSPITAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MEDICATION ERROR; NEUROLOGY; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; AGING; ANTICOAGULANTS; CEREBROVASCULAR ACCIDENT; FEMALE; HOSPITALS, COMMUNITY; HUMANS; INJECTIONS, INTRAVENOUS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; WARFARIN;

EID: 24944480687     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000178759.10773.73     Document Type: Review

References (13)

1. Albers GW, Bates VE, Clark WM, et al. intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA. 2000;283:1145-1150.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Bravata DM, Kim N, Concato J, et al. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med. 2002;162:1994-2001.
4. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland experience. JAMA. 2000;283:1151-1158.
5. Lopez-Yunez AM, Bruno A, Williams LS, et al. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. 2001;32:12-16.
6. Molina CA, Alvarez-Sabin J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002;33:1551-1556.
7. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke; the Houston Experience 1996 to 2000. Arch Neurol. 2001;58:2009-2013.
8. Katzan IL, Hammer MD, Furlan AJ, et al. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke. 2003;34:799-800.
9. Reed SD, Cramer SC, Blough DK, et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke. 2001;32:1832-1840.
10. Katzan IL, Hammer MD, Hixon ED, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61:346-350.
11. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke. 1997;1530-1540.
12. Williams LS, Yilmaz EY, Lopez-Yunez AM. Retrospective assessment of initial stroke severity with the NIH stroke scale. Stroke. 2000;31:858-862.
13. Furlan AJ, Kanoti G. When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective. Stroke. 1997;28:214-218.